The European Medicines Agency (EMA) has laid out its agenda for the Combination Products Operational Group under the Medical Devices (MD) stream, signaling a focused push on the regulation and oversight of combination medical products. This move is set to engage a variety of stakeholders, including medical device manufacturers, healthcare providers, regulatory bodies across the EU, and patients who rely on these complex products, likely stirring varied reactions based on compliance costs, patient safety priorities, and innovation impacts.
This agenda was published on 6 February 2026 by the EMA, which operates as the EU’s lead authority on medicines and medical devices regulation. The document outlines the operational group's planned discussions and focus areas for its meeting on 12 February 2026.
The agenda document is procedural and strategic in nature, rather than legislative. It lays out the key topics for deliberation and coordination within the operational group without proposing binding legislation. Although specific concrete regulatory proposals or targets are not included in this agenda, it sets the stage for detailed regulatory scrutiny and possible future initiatives regarding the integration of medical devices and medicinal products.
The EMA's orientation prioritizes enhancing regulatory clarity and cooperation between different regulatory domains (medical devices and pharmaceuticals), acknowledging the growing complexity of combination products. This approach implies an increase in regulatory scrutiny and coordination, possibly affecting timelines and approval processes, without immediate expansion of EU powers but improving inter-agency mechanisms.
Stakeholders such as medical device manufacturers might face increased administrative demands and the need for stricter compliance due to tighter integration and oversight. Conversely, patients and healthcare providers could benefit from improved safety and efficacy evaluations of combined products. National competent authorities and the EMA itself will see reinforced roles in the oversight process, increasing institutional workload and coordination efforts.
This agenda marks the continuation of an ongoing regulatory evolution process with the EMA setting the stage for more nuanced policy-making in combination products. The European Commission and national regulators are expected to engage subsequently, responding to the operational group's findings and potentially influencing future legislative updates or harmonization efforts in the medical devices sector.